A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia

Supportive Care in Cancer

Volumn 13, Issue 6, 2005, Pages 387-392

  Rossini, Fausto ^a   Terruzzi, Elisabetta ^a   Verga, Luisa ^a   Larocca, Alessandra ^a   Marinoni, Sara ^a   Miccolis, Isabella ^a   Giltri, Giuseppe ^a   Isella, Manuela ^a   Parma, Matteo ^a   Pogliani, Enrico M ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Amikacin; Antibiotic therapy; Ceftriaxone; Immunocompromised host; Piperacillin tazobactam

Indexed keywords

AMIKACIN; CEFTRIAXONE; PIPERACILLIN PLUS TAZOBACTAM;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLERGY; ARTICLE; BACTEREMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INFECTION; INTERMETHOD COMPARISON; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; TREATMENT OUTCOME;

EID: 21544463748     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0753-8     Document Type: Article

References (15)

1. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101-111
2. Schimpff SC (1995) Infections in cancer patients. In: Mandell GL, Douglas RG Jr, Benett JE (eds) Principles and practice of infectious diseases. Churcill Livingstone, London, pp 2666-2675
3. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247-259
4. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
5. Gilbert DN (1991) Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35:399-405
6. Indravadan H, Patel PD, Stanley A, Kaplan PD (1984) Pharmacokinetic profile of ceftriaxone in man. Am J Med 19:704-710
7. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer (1993) Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119:584-593
8. Rossini F, Pioltelli P, Bolis S, Borin L, Casaroli I, Lanzi E, Maffè P, Parma M, Tripputi P, Pogliani EM (1998) Ceftriaxone/amikacin vs ceftazidime/amikacin as empirical therapy for fever in patients with hematological malignancy and severe granulocytopenia. Clin Drug Investig 15:425-433
9. Rubin M, Pizzo PA (1988) Monotherapy in neutropenic cancer patients. In: Peterson PK, Verhoef J (eds) Antimicrobial agents, annual 3. Elsevier Science, New York, p 524
10. Hathorn JW, Rubin M, Pizzo PA (1987) Antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy. Antimicrob Agents Chemother 31:971-977
11. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, Rubin M, Jarosinski P, Gill V, Young RC (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165-176
12. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, Furno P, Russo D, D'Antonio D, Ricci P, Martino B, Mandelli F; Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Infection Program (2001) A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33:1295-1301
13. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP; International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 39:445-452
14. Rolston KVI, Tarrand JJ (1999) Pseudomonas aeruginosa - still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. Clin Infect Dis 29:463-464
15. Rossini F, Verga M, Pioltelli P, Giltri G, Sancassani V, Pogliani EM, Corneo G (2000) Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline-containing regimens. Haematologica 85:1255-1260